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Human mesangial cell production of monocyte chemoattractant pro-
tein.!: Modulation by lovastatin. Macrophages play a critical role in the
progression of clinical and experimental glomrular injury. Serum-stimu-
lated human fetal mesangial cells in culture produce a chemotactic factor
that is monocyte-selective. This chemotactic factor is most likely monocyte
chemoattractant protein-i (MCP-1) as a monoclonal antibody directed
against MCP-1, but not an irrelevant antibody, suppressed the mesangial
cell-derived chemotactic activity. Inhibition of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase by lovastatin resulted in a reduction
of the mesangial cell-derived chemotactic activity as well as MCP-1
mRNA expression. The inhibitory effects of lovastatin in the presence of
exogenous cholesterol were reversed by mevalonate, suggesting a role for
isoprenoid intermediates of the mevalonate pathway and/or isoprenylated
proteins in mesangial cell MCP-1 regulation. These findings suggest an
additional mechanism by which HMG-CoA reductase inhibition in vivo
may reduce glomerular injury.
The development of focal glomerulosclerosis in experimental
models of progressive renal disease is frequently characterized by
the presence of monocytes and monocyte-derived foam cells
[1—8]. Different maneuvers that deplete circulating monocytes
have been shown to reduce the degree of glomerular injury in
several experimental models [7—10}, underscoring the relevance of
monocyte-derived macrophage infiltration. The factors that gov-
em migration of monocytes into the glomerular mesangium and
their subsequent activation are incompletely understood. Mesan-
gial cells are known to produce a variety of chemotactic sub-
stances, including leukotrienes, and cytokines such as monocyte
chemoattractant protein-i (MCP-1) [i1—20J. Recent studies have
shown that MCP-i is the major monocyte chemoattractant se-
creted by stimulated mesangial cells [14, i9j.
Inhibitors of HMG-CoA reductase, such as lovastatin, have
been shown to reduce glomerular injury in different models of
progressive renal disease [21, 22]. The salutary effect of these
agents have been generally attributed to their ability to reduce
circulating lipids [21}. Preliminary reports suggest, however, that
HMG-CoA inhibitors may reduce glomerular as well as vascular
injury in vivo in the absence of significant effects on blood
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cholesterol levels [23—25]. It should be emphasized that these
agents, which block the synthesis of mevalonate, also inhibit the
synthesis of many other compounds derived from mevalonate
[26]. Mevalonate metabolism yields a series of isoprenoid com-
pounds which are incorporated into isopentenyl adenine, iso-
prenylated proteins, dolichol and other end products essential for
cell signalling and cell growth [26, 27]. We recently reported that
HMG-CoA reductase inhibition results in inhibition of mesangial
cell proliferation independently from the availability of choles-
terol [28], and others have confirmed this finding [29]. It is
conceivable that some mechanisms of cellular activation and
cytokine production may also be affected by HMG-CoA reductase
inhibition. In the present study, we examined whether human fetal
mesangial cell production of chemotactic factors for monocytes
might be modulated by lovastatin.
In the present experiments, we demonstrated that serum-
stimulated mesangial cells produced a chemotactic factor that is
monocyte selective. This factor was identified as MCP-1. Impor-
tantly, inhibition of mesangial cell HMG-CoA reductase by
lovastatin resulted in reduction of a secreted chemotactic protein
as well as a marked reduction in mesangial cell expression of
MCP-1 mRNA.
Methods
Human mesangial cell studies
Mesangial cell cultures. Human fetal mesangial cells were ob-
tained from an aborted human fetus. Permission to use this kidney
tissue was obtained from the Committee on Use of Human
Subjects in Research, University of Minnesota. Glomerular cores
were seeded on plastic tissue culture flasks and incubated at 37°C
in an atmosphere of 95% air and 5% CO2. The culture medium
was RMPI 1640 supplemented with 20% fetal bovine serum
(FBS). Fresh media was added every three to four days. For
selective passage of mesangial cells, ridges were removed and
replated in the same media. Details of the mesangial cell isolation
and culture techniques used in our laboratory as well as their
morphological characteristics have been reported [28, 30].
Experimental design. In all experiments 2 to 3 X iO mesangial
cells from the 4th to 6th passages were seeded on tissue culture
flasks and allowed to attach and grow to a semiconfluent state
over three to four days. Mesangial cells were then synchronized to
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quiescence in serum-free RPMI 1640 for 48 hours. After synchro-
nization, mesangial cells were exposed to 10% FBS as a mitogen
in the presence or absence of the HMG-CoA reductase inhibitor
lovastatin, a gift from Merck, Inc. (West Point, PA, USA). In
some experiments, mesangial cells were pretreated with lovastatin
for 16 hours before serum stimulation. Mesangial cell were
harvested at different times for RNA extraction and supernates
were harvested at 24 hours for evaluation of polymorphonuclear
(PMN) cell and monocyte chemotactic activity. In some experi-
ments, mevalonate was added at the time of serum stimulation to
assess the reversibility of HMG-CoA reductase inhibition as
previously described [28]. Lovastatin and mevalonate salts were
prepared as previously described [28].
Evaluation of chemotaxis
Leukocyte preparation. Heparinized blood obtained from
healthy donors was mixed with dextran, and red blood cells were
allowed to sediment to produce a leukocyte-rich supernatant.
Isolation of PMNs was performed as we have previously described
[31]. Briefly, the dextran-sedimented, leukocyte-rich supernatant
was centrifuged on discontinuous Ficoll-Hypaque (equal volumes
of specific gravity 1.080 and 1.120) and the cells were collected at
the interface of the bottom layer. Monocytes were obtained by a
modification of the Recalde method [32]. After recovering the
white cell fraction by centrifugation, they were incubated in a
slightly hypertonic solution for approximately 30 minutes at 37°C.
The monocytes were then separated using Ficoll-Hypaque and
density centrifugation [32].
Chemotaxis assay. Assessments of mesangial cell supernates for
chemotactic activity were performed in 48-well Neuroprobe®
chemotaxis chambers (Neuro Probe Inc., Cabin John, MD, USA).
The lower wells were loaded with 28 tl of the test solution and
covered with a 5 im pore size polycarbonate filter. Upper wells
were loaded with 50 .d of the cell suspension containing 5 X io
monocytes or PMNs. The chambers were incubated at 37°C for 1
or 1½ hours to assess chemotaxis of PMNs and monocytes,
respectively. The filters were then removed, fixed in methanol,
and stained with Duff-Quick (Baxter Healthcare Inc., Miami, FL,
USA). Migrating cells were evaluated by dividing a well into four
quadrants and adding the counts from one 200X field in each
quadrant. A total of three to five replicate wells were counted and
used for determination of the mean value of each data point.
Formyl-methionyl-leucyl-phenylalanine (FMLP; Sigma, St. Louis,
MO, USA) at a concentration of 1 x 108 M was used as the
standard chemoattractant for monocytes and PMN.
In certain experiments, the supernate chemotactic activity was
assayed after treatment with an affinity-purified IgG1 mouse
monoclonal antibody against human MCP-1, which was kindly
provided by T. Yoshimura, M.D., National Cancer Institute
(Frederick, MD, USA) [33]. Mesangial cell supernates were
incubated with varying dilutions of the MCP-1 antibody for one
hour at 37°C. Antibody and complexes were then removed from
the sample by ultrafiltration using an Amicon Centricon 100 filter
(Amicon Inc., Beverly, MA, USA) with an average molecular
cut-off of 100,000 daltons. As a control, similar protein concen-
trations of an irrelevant mouse IgG1 monoclonal antibody against
von Willebrand factor (Cappel Worthington, Malvern, PA, USA)
were added to supernates and processed as described above. Due
to the variability of the assay in different days, since the monocytes
came from different donors, the results are expressed as the
percentage of the appropriate control.
Results from one of two to four different experiments with
essentially identical results will be presented.
Molecular techniques
cDNA probes. The cDNA for human MCP-1 was a gift from T.
Yoshimura, M.D., and has been previously characterized [34].
The full length cDNA insert contains 739 base pairs and has been
shown to recognize a —0.8 kb mRNA from human mononuclear
and smooth muscle cells [34]. The cDNA insert was cloned in an
EcoRI site in pBluescript SK( —) plasmid. A cDNA for human
HMG-CoA reductase was obtained from American Type Culture
Collection (Rockville, MD, USA). The cDNA insert contains 4.3
kb, the full sequence for human HMG-CoA reductase that was
obtained from a fetal adrenal cDNA library [35]. The full length
cDNA was cloned in a pcDV 1 plasmid. After digestion with BglII,
a fragment of about 2.5 kb was isolated and used as a template for
radiolabeling. This fragment recognizes a mRNA of --4.2 kb from
human mesangial cells. A cDNA probe for 28s ribosomal RNA
was kindly provided by Dr. M.L. Iruela Arispe, University of
Washington (Seattle, WA, USA) [36]. The 280 bp fragment
between two EcoRI sites was used. Between 10 and 50 ng of a
cDNA template were labeled with 50 pCi of [32P]-dCTP using
Prime It II, a random primer DNA labeling system (Stratagene
Cloning System, La Jolla, CA, USA). The cDNAs were purified
on a Nuctrap probe purification column (Stratagene Cloning
System). The specific activity varied between 1 and 2 X i09
cpm/j.tg cDNA.
Northern blot analysis. Total RNA was isolated from mesangial
cells by a modification of the single step guanidinium-thiocyanate-
phenol-chloroform extraction method [37]. The RNA was quan-
tified by absorbance at 260 nm and its purity assessed by the ratio
of absorbance at 260:280 being greater than 1.8 to 2.0. Ten to 20
j.g samples of denatured mesangial cell RNA together with 10 tg
of a RNA ladder (BRL Inc., Gaithersburg, MD, USA) were
electrophoresed in a 1.0% agarose gel containing 2.2 M formal-
dehyde, 20 mrvt MOPS, 8 mM sodium acetate and 1 mM EDTA,
stained with ethidium bromide and photographed to assess deg-
radation, molecular size and equivalent RNA loading. The elec-
trophoresed RNA was transferred to a Zeta Probe membrane
(Bio-Rad, Richmond, CA, USA). The membrane was air dried
and baked at 80°C for 30 to 60 minutes in a vacuum oven and
stored at room temperature until needed. Blotted membranes
were incubated with 1.5 X 106 cpm/ml of a labeled cDNA probe
in standard hybridization solution for 12 to 24 hours, subjected to
a series of stringency washes and exposed on Kodak X-OMAT
XAR5 at —70°C. To assess that equivalent amounts of RNA were
loaded, the membranes were stripped and reprobed for 28s
ribosomal RNA. Autoradiograms of the probed RNA were
scanned by densitometry and normalized to the respective 28s
values. A representative Northern blot analysis from two to four
different experiments is shown.
Statistical analysis
Results were expressed as mean SEM. The significance of
differences between the means of two groups was tested by the
unpaired Student's t-test. When more than two groups were
compared, significance was tested using analysis of variance.
These analyses were performed using the Statistical Package for
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Fig. 1. Quiescent human fetal mesangial cells when stimulated to proliferate
with 10% fetal bovine serum secreted a factor that stimulated chemota.xis of
normal peripheral blood monocytes (hatched bar). Quiescent mesangial
cells maintained in serum-free RPMI (open bar) did not secrete a
significant amount of this factor. As a positive control the effect of 10_8 M
FMLP is also displayed (solid bar). Abbreviations are: M, monocytes;
FMLP, formyl-methionyl-leucyl-phenylalanine; FBS, fetal bovine serum.
Social Sciences 38]. Differences were considered significant for P
<0.05.
Results
Mesangial cell production of a chemotactic factor
Quiescent human fetal mesangial cells, when exposed to 10%
FBS for 24 hours, secreted a factor that stimulated chemotaxis of
normal human peripheral blood monocytes. This effect was
quantitatively similar to that seen when the chemotactic peptide
FMLP was used to stimulate monocyte chemotaxis (Fig. 1). In
contrast, no effect on chemotaxis of PMNs was seen with super-
nates from serum-stimulated mesangial cells (data not shown).
Quiescent mesangial cells maintained in serum-free RPMI did not
secrete significant amounts of chemotactic factor during the
24-hour incubation (Fig. 1). Similarly, 10% FBS alone in the
chemotaxis chamber did not demonstrate any significant chemo-
tactic activity (data not shown). Ultrafiltration of mesangial cell
supernates after incubation with a serial dilution of an IgG1
mouse monoclonal antibody against human monocyte MCP-1
resulted in a dose-response reduction in the supemate chemotac-
tic activity (Fig. 2). Ultrafiltration alone (not shown) or after
incubation with a comparable concentration of an irrelevant IgG
mouse monoclonal antibody (anti-von Willebrand factor) had no
effect on monocyte chemotaxis of the mesangial cell supernates
(Fig. 2).
Effect of inhibition of HMG-CoA reducrase on production of
mesangial cell MCP-1
Lovastatin, in a concentration-dependent manner, inhibited
mesangial cell production of a monocyte chemotactic factor (Fig.
3). Between 20 and 40% of chemotactic activity in the supernates
was inhibited by ito 20 .iM lovastatin. The addition of the MCP-1
monoclonal antibody to these supernates followed by ultrafiltra-
tion virtually abolished the remaining chemotactic activity (data
not shown). The mesangial cell viability, as assessed by trypan blue
exclusion, was similar in control cells and in lovastatin treated
cells (>85%). In separate experiments, the addition of lovastatin
to the chemotaxis chambers did not alter the chemotaxis of
monocytes to FMLP nor did it affect the chemotactic response to
the mesangial cell-derived chemotactic factor (data not shown).
The addition of mevalonate to the mesangial cell incubation
medium at the time of serum stimulation completely reversed the
inhibitory effect of lovastatin and restored mesangial cell produc-
tion of the chemotactic factor (Fig. 4). The addition of mevalonate
to the medium in the absence of lovastatin did not modify the
monocyte chemotactic activity (not shown).
Effect of HMG-CoA reductase inhibition on MCP-1
mRNA expression
To evaluate whether lovastatin influenced the steady state level
of mRNA for MCP-i after 24 hours, total RNA was obtained
from serum-stimulated mesangial cells in the presence of lova-
statin with or without mevalonate. In these experiments, total
RNA was also probed for HMG-CoA reductase mRNA to
ascertain the effectiveness of lovastatin inhibition of HMG-CoA
reductase. Quiescent mesangial cells had minimal constitutive
expression of MCP-1 (Fig. 5). This was consistent with our results
demonstrating virtually no detectable chemotactic activity in the
supernates from quiescent mesangial cells (Fig. 1). In contrast,
serum-stimulation of mesangial cells resulted in a significantly
increased expression of MCP-1 mRNA (Fig. 5). This effect was
virtually suppressed by lovastatin, while mevalonate completely
reversed the effects of HMG-CoA reductase inhibition (Fig. 5).
Consistent with the effect of lovastatin to inhibit HMG-CoA
reductase, lovastatin markedly up-regulated mRNA expression
for this enzyme, while the addition of mevalonate significantly
down-regulated the expression of this mRNA (Fig. 6).
Time-dependent effect of HMG-CoA reductase inhibition on
MCP-1 mRNA expression
To assess the apparent discrepancy between the total suppres-
sion of MCP-i mRNA at 24 hours and the only partial (20 to
40%) inhibition of chemotactic activity in 24 hour supernates,
MCP-1 mRNA expression was evaluated at earlier time points
after serum stimulation. Serum-stimulated mesangial cells exhib-
ited a marked up-regulation of MCP-1 mRNA expression that
reached a peak between three and six hours and declined there-
after (Fig. 7). Lovastatin inhibited MCP-1 mRNA expression only
after six hours of incubation, and had little effects at earlier times.
This late inhibition of MCP-1 mRNA expression by lovastatin may
have permitted an early MCP-1 production and accumulation in
the 24 hour supernates that were used for chemotactic assays. The
delayed effects of lovastatin suggest that an incubation period is
required for the action of the drug. Alternatively, it may reflect a
specific effect on the time dependent events of MCP-i mRNA
up-regulation following serum stimulation, that is, lovastatin
might produce a late down-regulation without affecting the initial
response. To discern between these two possibilities, mesangial
cells were preincubated with lovastatin for 16 hours before serum
stimulation, When mesangial cells were preincubated with lova-
statin, MCP-1 mRNA up-regulation was prevented from the
beginning (Fig. 8). Therefore, these results are consistent with the
necessity of an incubation period of several hours for lovastatin
effects. In either case, when the cells were exposed to mevalonate
for at least three hours, the inhibitory effects of lovastatin were
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Fig. 2. Quiescent human fetal mesangial cells
were stimulated with 10% fetal bovine serum and
the 24 hour supemates were assayed for monocyte
chemotactic activity as described in Methods
(open bar). Aliquots of supernates were
incubated with different concentrations of a
monoclonal IgG antibody against human MCP-
1 (hatched bars) or an irrelevant IgG antibody
(von Willebrand, solid bar), ultrafiltered and
assayed for monocyte chemotactic activity.
Ultrafiltration alone had no effect on
chemotactic activity (not shown). Abbreviations
are: M4, m000cytes; FBS, fetal bovine serum;
MoAb, monoclonal antibody; MCP-1, monocyte
chemoattractant protein-i.
clonal antibody against MCP-1, but not by an irrelevant IgG
antibody. It is reasonable to conclude that this chemotactic
activity was indeed due to mesangial cell secretion of MCP-1.
Mesangial cells can produce several products with chemotactic
activity such as transforming growth factor (TGF) /31 and platelet-
derived growth factor (PDGF). However, their contribution to the
monocyte chemotactic activity in our experimental conditions
appears to be negligible. Other investigators have also found that
most of the monocyte chemotactic activity secreted by cytokine or
lipopolysaccharide (LPS) stimulated mesangial cells can be sup-
pressed by antibodies against MCP-1 [14, 191. Similar results have
been obtained in cultures of smooth muscle cells, cells that exhibit
many similarities with mesangial cells, after stimulation with
oxidatively-modifled lipoproteins [53, 54]. It is, therefore, possible
that some of the mesangial cell monocyte chemotactic activity
previously attributed to different cytokines may be in fact due to
MCP-1 production. Indeed, PDGF, TGF-f31, LPS and modified
lipoproteins are all potent inducers of MCP-1 expression [19, 43,
44, 53—551.
Recent experimental evidence suggests that some beneficial
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Fig. 3. Lovastatin (1 to 20 pM) caused a significant (P < 0.01, ANOVA)
dose-dependent reduction in 24 hour production of a monocyte chemotactic
factor by serum-stimulated human fetal mesangial cells. Mø is monocytes.
substantially reversed (Figs. 7 and 8). It is conceivable that a
minimum time is required for cell uptake and metabolism of
mevalonate to reverse lovastatin effects. In the absence of lova-
statin, mevalonate did not affect mesangial cell MCP-1 mRNA
expression (data not shown).
Discussion
MCP-1 production has been recently demonstrated in a variety
of human and rodent cells [34, 39—44]. Increased glomerular
expression of MCP-1 has been shown within minutes of induction
of anti-Thy 1.1 glomerulonephritis [45], a model of mesangial cell
injury associated with early mesangial monocyte infiltration [45].
Preliminary studies have also found an association between
increased renal expression of MCP-1 and monocyte infiltration in
a variety of immunologic and non-immunologic models of renal
injury [46—51]. A number of growth promoting and inflammatory
cytokines have been shown to increase the expression of MCP-1
mRNA as well as the secreted peptide [14, 34, 40, 42—44, 52].
Glomerular mesangial cells have also been shown to produce
MCP-1 in response to a variety of stimuli [13—20, 52].
The present results confirm previous reports suggesting that
mitogen-stimulated mesangial cells produce monocyte chemoat-
tractants. The chemotactic activity was selective for monocytes, as
no chemotactic activity was detected for PMNs. Virtually all the
monocyte chemotactic activity was suppressed by an IgG mono-
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Fig. 4. In these experiments 5 M lovastatin significantly reduced (hatched
bar) serum-stimulated human fetal mesangial cell production of a chemo-
tactic factor for monocytes. This was completely restored by the addition of
iQO LM mevalonate (solid bar). *jD < 0.OOi. Abbreviations are: M4i,
monocytes; FBS, fetal bovine serum.
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Fig. 5. Northern analysis (A) and densitometric evaluation (B) ofMCP-1
mRNA in serum-stimulated human fetal mesangial cells (lane 1, open bar).
The presence of 5 .rM lovastatin dramatically reduced MCP-1 mRNA
expression (lane 2, hatched bar). The presence of 100 JLM mevalonate
completely reversed the inhibitory effect of lovastatin (lane 3, solid bar).
Quiescent mesangial cells maintained in serum-free RPMI demonstrated
a low constitutive expression of MCP-1 (lane 4, double hatched bar). The
ethidium bromide picture of the gel is shown as an insert. The membrane
reprobed for 28s ribosomal RNA is also shown. B. Densitometric evalu-
ation of the Northern blot after normalization with 28s ribosomal RNA.
Abbreviations are: O.D., optical density, arbitrary units; FBS, fetal bovine
serum; MCP-1, monocyte chemoattractant protein-i. Symbols are: (E])
FBS; () Lovastatin; (U) Lovastatin + Mevalonate; () RPMI.
effects of HMG-CoA reductase inhibition can be obtained in the
absence of significant changes in circulating cholesterol [23—251.
Our data suggest another potential mechanism by which lovasta-
Fig. 6. Northern analysis of HMG-CoA reductase mRNA in serum-stimu-
lated human fetal mesangial cells (lane 1, open bar). In accordance with the
metabolic effects of lovastatin and mevalonate, HMG-CoA reductase
mRNA expression was significantly up-regulated by 5 jrM lovastatin (lane
2, hatched bar) and markedly down-regulated after the addition of 100 rM
mevalonate (lane 3, solid bar). The ethidium bromide picture of the gel is
shown as an insert. The membrane reprobed for 28s ribosomal RNA is
also shown. B. Densitometric evaluation of the Northern blot after
normalization with 28s ribosomal RNA. Abbreviations are: HMG-CoA R,
3-hydroxy-3-methylglutaiyl coenzyme A reductase; O.D., optical density,
arbitrary units; FBS, fetal bovine serum. Symbols are: (EJ) FBS; ()
Lovastatin; (U) Lovastatin + Mevalonate.
tin affords glomerular protection, namely, inhibition of mesangial
cell production of MCP-1 and subsequent monocyte recruitment.
The reduction of MCP-1 production by lovastatin involves, at
least, the inhibition of MCP-1 mRNA up-regulation. Although
the inhibition of MCP-1 mRNA expression may account com-
pletely for the lovastatin inhibition of MCP-1 production, other
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Fig. 7. Time-dependent effects of lovastatin on MCP-1 mRNA expression.
Quiescent human fetal mesangial cells were stimulated with 10% fetal
bovine serum in the absence (lanes A, open bars) or presence (lanes B,
hatched bars) of 5 sM lovastatin. Some lovastatin-treated cells were
exposed to 100 tLM mevalonate (lanes C, solid bars). Total RNA was
extracted at different times following serum stimulation, blotted, and
probed for MCP-i as described in Methods. Lovastatin inhibited MCP-1
mRNA up-regulation only after six hours of incubation. This late lovas-
tatin inhibition was reversed by mevalonate. The ethidium bromide
picture of the gel is shown as an insert. The membrane reprobed for 28s
ribosomal RNA is also shown. The lower panel shows the densitometric
evaluation of the Northern blot after normalization with 28s ribosomal
RNA. Abbreviations are: MCP-1, monocyte chemoattractant protein-i;
O.D., optical density, arbitrary units; FBS, fetal bovine serum. Symbols
are: (fl) FBS; () Lovastatin; (R) Lovastatin + Mevalonate.
potential effects of lovastatin on mesangial cell translation, post-
translational regulation and secretion of MCP-1 cannot be ruled
out with the present data. The lovastatin inhibition of MCP-i
production and mRNA expression appears to be specific and not
a toxic effect for several reasons. First, the number of mesangial
cells as well as their viability were not significantly affected by
lovastatin treatment. Second, mesangial cells were able to up-
regulate HMG-CoA reductase mRNA levels in response to
lovastatin inhibition of this enzyme. In case of a non-specific toxic
effect this up-regulation would also likely have been inhibited.
Third, in similar studies lovastatin did not affect the expression of
other unrelated genes such as the a1 chain of type IV collagen,
TGF-pl and PDGF-B [56—58]. Grandaliano et al have also found
that a similar concentration of simvastatin, another HMG-CoA
reductase inhibitor, did not affect mesangial cell mRNA expres-
sion for PDGF-B [29}. Finally, mevalonate, the first product of the
pathway inhibited by lovastatin, reversed lovastatin effects, sug-
gesting that the lovastatin effect was indeed specific to the
inhibition of mevalonate production.
Increasing experimental data suggest that, besides cholesterol,
different products of the mevalonate pathway play important roles
in mesangial cell biology [27, 59]. We and others have reported
that mesangial cell proliferation is dependent on the isoprenoid
metabolites of this pathway and that HMG-CoA reductase inhi-
bition could therefore result in glomerular protection by the
inhibition of mesangial cell proliferation [28, 29]. The present
results suggest that mevalonate metabolites are also required for
mesangial cell mRNA expression and production of MCP-1.
Cholesterol depletion cannot be implicated for the lovastatin
inhibition of MCP-1 production, as an exogenous source of
cholesterol was provided by the serum-supplemented medium in
all of the experiments.
Of particular interest was the observation that an incubation
period of several hours was required to detect the effects of
lovastatin on MCP-l mRNA. Few studies have addressed the
time-dependent changes after the addition of lovastatin to the cell
culture. Repco and Maltese reported that, in the MEL cell line,
lovastatin depletes the cellular pool of isoprenoids in less than one
hour [60]. However, seven hours of incubation with lovastatin
were required to produce a significant (20 to 35%) reduction in
the cellular content of isoprenylated proteins [60j. The time
course of lovastatin effects on the cellular levels of isoprenylated
proteins in MEL cells is remarkably similar to the effects of
lovastatin on MCP-1 mRNA expression in our mesangial cell
system. If the effects of lovastatin on the mevalonate pathway in
mesangial cells follow a similar sequence to that described in
MEL cells, a direct role for isoprenoids themselves in mesangial
cell regulation of MCP-1 does not seem likely. Rather, an
involvement of isoprenylated proteins or other long-lived meval-
onate derived compounds is suggested. However, the specific
roles of the isoprenoids of the mevalonate pathway and/or isopre-
noid-modified proteins in the regulation of mesangial cell MCP-l
production were not assessed in the present study and warrant
further investigation.
In summary, our data confirm previous reports suggesting that
stimulated mesangial cells secrete chemotactic substances for
monocytes and that most of this chemotactic activity can be
attributed to the production of MCP-l. The present results also
indicate that the mesangial cell production of MCP-l is depen-
dent on metabolites of the mevalonate pathway. Thus, our
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Fig. 8. Effects of lovastatin preincubation on
MCP-1 mRNA expression. Human fetal
mesangial cells were rendered quiescent by
incubation in serum-free medium for 48 hours.
During the last 16 hours of this period,
mesangial cells were exposed to 5 M
lovastatin. At time 0, the cells were extensively
washed and stimulated with 10% fetal bovine
serum in the absence (lanes A, open bars) or
presence (lanes B, hatched bars) of 5 M
lovastatin. Some cells were exposed to 100 M
mevalonate in addition to 5 M lovastatin
(lanes C, solid bars) at the time of serum
stimulation. Total RNA was extracted at
different times, blotted, and probed for MCP-1
as described in Methods. Lovastatin inhibited
MCP-1 mRNA up-regulation from the
beginning. When mevalonate was present in the
cell culture for more than three hours, it
essentially reversed lovastatin inhibition. The
ethidium bromide picture of the gel is shown as
an insert. The membrane reprobed for 28s
ribosomal RNA is also shown. The lower panel
shows the densitometric evaluation of the
Northern blot after normalization with 28s
ribosomal RNA. Abbreviations are: MCP-1,
monocyte chemoattractant protein-i; O.D.,
optical density, arbitrary units; FBS, fetal
bovine serum. Symbols are: (0) FBS; (J)
Lovastatin; (U) Lovastatin + Mevalonate.
findings provide another potential mechanism whereby HMG-
CoA reductase inhibitors may exert beneficial effects to amelio-
rate progressive renal injury.
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